eMethods. Anticoagulant treatment
Patients in both study groups received full-dose anticoagulant therapy according to guidelines. 1 Treatment was initiated with unfractionated heparin (mandatory in patients with a creatinine clearance of 30 ml per minute or less), low-molecular-weight heparin or fondaparinux. Parenteral anticoagulant treatment overlapped with vitamin K antagonist therapy (the type being left to the investigator's discretion) and was continued for at least five days and until the international normalized ratio (INR) was above 2.0 for two consecutive days. Vitamin K antagonist therapy was continued for six months with adjustment of the dose to maintain the INR between 2.0 and 3.0, values being determined at least once a month. Patients with active cancer (without severe renal insufficiency) were to received low-molecular-weight heparin for six months rather than vitamin K antagonist therapy.
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Interim statistical analysis
An interim analysis after inclusion and follow-up of the first 200 patients was planned to check whether the study should be stopped due to futility or early efficacy. The trial was to be stopped for futility if the upper limit of the 95% confidence interval (CI) of the incidence of the primary outcome in the control group was below 4%. The observed incidence was 1.7% (95% CI, 0.2 to 6.1%). The interim efficacy analysis was performed using Peto methods for stopping and for protecting the type I error. 2, 3 Early efficacy was defined as a significant difference between the two groups at the two-sided threshold of α=0.001. This analysis showed that, by three months, recurrent pulmonary embolism had occurred in 2 of 116 patients (1.7%) in the control group and in 3 of 114 patients (2.6%) in the filter group (relative risk with filter, 1.53; 95% CI, 0.26 to 8.96; P=0.64). Based on these results, the independent data and safety monitoring committee recommended that the study be continued as planned, a recommendation that was followed by the steering committee without knowledge of the outcomes in the two study groups.
Outcome definitions
Recurrent fatal or symptomatic non-fatal pulmonary embolism and recurrent or new deep-vein thrombosis were objectively confirmed on the basis of previously described criteria.
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Recurrent pulmonary embolism
Symptoms of pulmonary embolism with one of the following findings:
• A new intraluminal filling defect on spiral CT or pulmonary angiography, • A new cut-off of vessels more than 2.5 mm in diameter on pulmonary angiography, • A new perfusion defect concerning at least 75% of a segment with corresponding normal ventilation on ventilation/perfusion lung scan (i.e., a high-probability lung scan), • A new non-diagnostic lung scan associated with deep-vein thrombosis as documented by ultrasonography or venography, or • A new pulmonary embolism confirmed at autopsy.
Pulmonary embolism was considered to be the cause of death if there was objective documentation or if death could not be attributed to any other documented cause and pulmonary embolism could not be ruled out.
Recurrent or new deep-vein thrombosis
Symptoms of deep-vein thrombosis with one of the following findings:
• A new non-compressible venous segment or a substantial increase (of 4 mm or more) in the diameter of the thrombus during full compression in a previously abnormal segment on ultrasonography, or • A new intraluminal filling defect on venography.
Major bleeding
Bleeding was defined as major if it was overt and met at least one of the criteria listed by the International Society on Thrombosis and Haemostasis for the definition of major bleeding in non-surgical patients: 6 • Fatal • In a critical organ (e.g. intracranial, intraspinal, intraocular, retroperitoneal, pericardial or adrenal)
• Associated with a fall in hemoglobin concentration of 2 g/dL or more compared with baseline, • Leading to transfusion of two or more units of packed red blood cells or whole blood.
Filter complications
Filter complications were assessed according to definitions based on those adopted by the Society of Interventional Radiology. 7, 8 • Migration: cranial or caudal change in filter position of more than 20 mm compared with initial position as documented by plain film imaging, computerized tomography, or venography.
• Tilting: deviation greater than 15° from the central axis of the vena cava as assessed by cavography.
• Penetration: extension of filter strut or anchor device more than 3 mm beyond the wall of the inferior vena cava demonstrated by computerized tomography, ultrasounds, venography, or autopsy.
• Access site hematoma: any hematoma with a size of 100 cm 2 or more, or leading to an increase of more than 24 hours in compression time, or necessitating bed rest or an increase in bed rest time, or leading to a change in anticoagulant treatment, or leading to transfusion of one unit or more of packed red blood cells or whole blood.
• Infection: any local or systemic infection related to filter insertion or retrieval and necessitating antibiotic therapy.
All abdominal X-ray examinations were read centrally by a vascular radiologist. 
